Lead Product(s): PHA121
Therapeutic Area: Genetic Disease
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
The objective of the study was to investigate the ability of PHA121 to attenuate blood-pressure changes induced by bradykinin injection.